幽门螺杆菌若干问题的共识意见

1999年4月29～30日,全国幽门螺杆菌(Ｈ.ｐｙｌｏｒｉ)科研协作组邀请国内Ｈ.ｐｙｌｏｒｉ研究专家56人在海南省三亚市举行我国第一次Ｈ.ｐｙｌｏｒｉ专家共识会议。会议主要对Ｈ.ｐｙｌｏｒｉ的诊断、与胃癌和功能性消化不良(ＦＤ)的关系及抗Ｈ.ｐｙｌｏｒｉ治疗等进行了较充分的研讨,并对Ｈ.ｐｙｌｏｒｉ的流行病学、致病机理进行了讨论。在此基础上请与会专家对Ｈ.ｐｙｌｏｒｉ的41个有关问题进行书面表决,再将讨论及反馈意见汇总形成初步的共识意见稿,返回各位专家修改,集中后提交到1999年10月在西安举行的第六届全国消化系病学术大会进…     

幽门螺杆菌若干问题的共识意见

1999年4月29—30日,全国幽门螺杆菌(H．pylori)科研协作组邀请国内H．pylori研究专家56人在海南省三亚市举行我国第一次H．pylori专家共识会议。会议主要对H．pylori的诊断、与胃癌和功能性消化不良(FD)的关系及抗H．pylori治疗等进行了较充分的研讨,并对H．pylori的流行病学、致病机理进     

幽门螺杆菌若干临床方面的共识意见(2003·安徽桐城)

1999年海南会议提出并经全国消化大会确认的我国“对幽门螺杆菌若干问题的共识意见”于2 0 0 0年发表至今已3年余[1] 。3年多来,对幽门螺杆菌(Helicobacterpylori,简称H .pylori或简写为Hp)的一些重要问题又有了新的认识,2 0 0 0年欧洲Maastricht- 2共识报告具有重要的指导意义[2 ] ,2 0 0 2年第三届全国Hp会议上广泛听取了大家对“共识”的意见,又经2 0 0 3年安徽桐城全国Hp共识会议(简称桐城会议)审核修订,现提出新的Hp共识意见,以便在推广应用中充实和完善。一、Hp感染及其相关疾病流行病学调查表明,Hp在一些国家或地区人群中的感染…     

幽门螺杆菌若干问题的共识意见

1999-04-29/30,全国幽门螺杆菌(H.pylori)科研协作组邀请国内H.pylori研究专家56人在海南省三亚市举行我国第一次H.pylori专家共识会议.会议主要对H.pylori的诊断、与胃癌和功能性消化不良(FD)的关系及抗H.pylori治疗等进行了较充分的研讨,并对H.pylori的流行病学、致病机制进行了讨论.在此基础上请与会专家对H.pylori的41个有关问题进行书面表决,再将讨论及反馈意见汇总形成初步的共识意见稿,返回各位专家修改,集中后提交到1999年10月在西安举行的第六届全国消化系病学术大会进行讨论,现将各方意见总结如下.     

幽门螺杆菌与功能性消化不良

消化不良是指持续或反复发作的上腹痛或不适 ,包括不同程度和性质的上腹痛、上腹胀、早饱、嗳气、恶心等上腹部症状 ,病程超过 2周。功能性消化不良 (ＦＤ)是指有消化不良而经详尽的检查未能发现引起这些症状的局部或全身器质性病变[1] 。ＦＤ的病因及发病机制未明 ,目前认为是多种因素引起的临床综合征。自幽门螺杆菌 (Ｈｐ)发现以来 ,Ｈｐ与ＦＤ的关系便受到关注 ,因为ＦＤ患者中有30 %～ 6 0 %有Ｈｐ感染及由此而引起的慢性活动性胃炎。然而 ,十多年来大量的研究却一直未能为两者的关系提供明确的证据 :(1)不少调查表明 ,在ＦＤ患者中Ｈ…     

幽门螺杆菌临床研究中有争议的若干问题

幽门螺杆菌(Hp)阳性的功能性消化不良是否应根除Hp?在临床上，有时将慢性胃炎与功能性消化不良(FD)作为“同义词”，应该说两存在差异。慢性胃炎强调胃黏膜组织学改变，多数(75％～85％)病人并无消化不良症状；而FD则强调消化不良症状，部分病人可无慢性胃炎。     

幽门螺杆菌若干问题的共识意见

1999年4月29～30日,全国幽门螺杆菌(Ｈｐ)科研协作组邀请国内Ｈｐ研究专家56人在海南省三亚市举行我国第一次Ｈｐ专家共识会议。会议主要对Ｈｐ的诊断、其与胃癌和功能性消化不良(ＦＤ)的关系及抗Ｈｐ治疗等进行了较充分的研讨,并对Ｈｐ的流行病学、致病机制进行了讨论。在此基础上请与会专家对Ｈｐ的41个有关问题进行书面表决,再将讨论及反馈意见汇总形成初步的共识意见稿,返给各位专家修改,集中后提交到1999年10月在西安举行的第六次全国消化系病学术大会进行讨论,现将各方意见总结如下。关于幽门螺杆菌属细菌的英文缩写,国际上已有规范,…     

抗幽门螺杆菌感染治疗功能性消化不良

幽门螺杆菌（Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ,Ｈｐ）感染与消化性溃疡及胃癌的相关已得到公认,但其与功能性消化不良（ｆｕｎｃｔｉｏｎａｌｄｙｓｐｅｐｓｉａ,ＦＤ）的关系目前尚存在争议［１］,我们拟从抗Ｈｐ治疗对ＦＤ患者症状的改善,来探讨抗Ｈｐ感染在...     

功能性消化不良与幽门螺杆菌关系的研究进展

功能性消化不良(FD)患者感染幽门螺杆菌(H.pylori)十分常见,H.pylori对于FD的发病过程有重要意义。本文旨在总结H.pylori在FD发病过程中的作用和根除H.pylori治疗对FD疾病进程影响的相关研究进展。     

幽门螺杆菌感染与功能性消化不良

功能性消化不良(FD)是指有消化不良症状,但经检查排除了引起这些症状的器质性疾病,并在过去12个月中症状至少存在12周的症征。FD根据主要症状又可分为以疼痛为主的溃疡样(ulcer like)型、以上腹饱胀不适为主的动力障碍样(dysmotility like)型以及难以归入上述二型的非特异(unsp     

Second Brazilian Consensus Conference on Helicobacter pylori infection

Significant progress has been obtained since the First Brazilian Consensus Conference on H. pylori Infection held in 1995, in Belo Horizonte, MG, and justify a second meeting to establish updated guidelines on the current management of H. pylori infection. The Second Brazilian Consensus Conference on H. pylori Infection was organized by the Brazilian Federation of Gastroenterology and Brazilian Nucleus for the Study of Helicobacter and took place on June, 19-20, 2004 in S?o Paulo, SP. Thirty six delegates coming from 15 different Brazilian states including gastroenterologists, pathologists, microbiologists and pediatricians undertook the meeting. The participants were allocated in one the five main topics of the meeting: H. pylori and dyspepsia, H. pylori and NSAIDs, H. pylori and gastroesophageal reflux disease, H. pylori treatment, and H. pylori retreatment. Seventy per cent and more votes were considered as acceptance for the final statement. The results were presented during a special session on the VI Brazilian Week of Digestive System, in Recife, PE (October 2004), and this publication represents the summary of the main recommendations and conclusions emerged from the meeting.     

Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection

The Asia–Pacific Consensus Conference was convened to review and synthesize the most current information on Helicobacter pylori management so as to update the previously published regional guidelines. The group recognized that in addition to long-established indications, such as peptic ulcer disease, early mucosa-associated lymphoid tissue (MALT) type lymphoma and family history of gastric cancer, H. pylori eradication was also indicated for H. pylori infected patients with functional dyspepsia, in those receiving long-term maintenance proton pump inhibitor (PPI) for gastroesophageal reflux disease, and in cases of unexplained iron deficiency anemia or idiopathic thrombocytopenic purpura. In addition, a population 'test and treat' strategy for H. pylori infection in communities with high incidence of gastric cancer was considered to be an effective strategy for gastric cancer prevention. It was recommended that H. pylori infection should be tested for and eradicated prior to long-term aspirin or non-steroidal anti-inflammatory drug therapy in patients at high risk for ulcers and ulcer-related complications. In Asia, the currently recommended first-line therapy for H. pylori infection is PPI-based triple therapy with amoxicillin/metronidazole and clarithromycin for 7 days, while bismuth-based quadruple therapy is an effective alternative. There appears to be an increasing rate of resistance to clarithromycin and metronidazole in parts of Asia, leading to reduced efficacy of PPI-based triple therapy. There are insufficient data to recommend sequential therapy as an alternative first-line therapy in Asia. Salvage therapies that can be used include: (i) standard triple therapy that has not been previously used; (ii) bismuth-based quadruple therapy; (iii) levofloxacin-based triple therapy; and (iv) rifabutin-based triple therapy. Both CYP2C19 genetic polymorphisms and cigarette smoking can influence future H. pylori eradication rates.     

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

Management of Helicobacter pylori infection is evolving and in this 4th edition of the Maastricht consensus report aspects related to the clinical role of H pylori were looked at again in 2010. In the 4th Maastricht/Florence Consensus Conference 44 experts from 24 countries took active part and examined key clinical aspects in three subdivided workshops: (1) Indications and contraindications for diagnosis and treatment, focusing on dyspepsia, non-steroidal anti-inflammatory drugs or aspirin use, gastro-oesophageal reflux disease and extraintestinal manifestations of the infection. (2) Diagnostic tests and treatment of infection. (3) Prevention of gastric cancer and other complications. The results of the individual workshops were submitted to a final consensus voting to all participants. Recommendations are provided on the basis of the best current evidence and plausibility to guide doctors involved in the management of this infection associated with various clinical conditions.